{"name":"Norwegian Breast Cancer Group","slug":"norwegian-breast-cancer-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeVB5TkdHcktxR0lYY0tGTDN1OVhVWjhzdTNneVdhdlYyd05QMHowUVJTb0R5R2VUcUptTEs5WjJ0QVgwdVFQbnNldXc1T2l6N19uRkdPS1dVa2xZNE1hSDJJc2NRRGFyUkR1bDlXQjUyckRuMFNvLXNLX2NEaXEtWklTUTRISUw1SF8w?oc=5","date":"2026-03-03","type":"pipeline","source":"Statista","summary":"Cancer incidence in Norway from 2020 to 2024, by age group - Statista","headline":"Cancer incidence in Norway from 2020 to 2024, by age group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNUXhuYUNKRFFNWk90RnY4bTdIRmV5cjdsMUVISHQ5bW5ENk02QzF2SUQtRzJ4dUJxRUZkbXNRcTNNc1hzdlA2OVl2eFk3STl4c0JQeVk4dWZaUFdRemlDTy16djk2aktDQ1hZem9DYlhwdWMxSVoyOW1MTUVLNG16OVQtZjg4S2M?oc=5","date":"2025-07-14","type":"pipeline","source":"Medical Xpress","summary":"Anti-nausea medication linked to higher survival rates in women with triple negative breast cancer - Medical Xpress","headline":"Anti-nausea medication linked to higher survival rates in women with triple negative breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPN3ZrYS0xT0lub2hoWlhicGVQRFZaeVpLNUI2bGpid21FVDRrMVhiZ1ZWaXI2WlZxTUZrOXllWTFtVnBzN1haUVdFTXAxY3BVUDdtV0tScF9ETUZXVy1VUkN5UUtwRG9Mcjdqd3VsOC1lU0NITDhKSTgxOVB5bFdnVG56R2lHU2NHRzdFVXBHcThTRkFKdDBLbXVpbndtdFdxaHdqYzhpbmVMOU1TOGRuLUtMQ0FpV1VlMk5od3pLb1RWWmU3SnZqZ1FpdWt3ZFJqdVlBUHlWRlBuSXRpYUEtZVVqRS1aNEYtS3M1ckxQOXRjUXJQS08waEVnVUlGeTVPUmQwMWZLRy1ZUG1lN19fNy1DRm9yVEZZWG1CN1N3?oc=5","date":"2025-01-28","type":"pipeline","source":"prnewswire.com","summary":"Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings - prnewswire.com","headline":"Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPUDk4d2xRVTF5Vk1HM0hKcVQxRkdrUUIxRDc1RzM2dlJ2dC1SbGRWdnlNbEREVnRXRks0N1ZvSWM0Z2oxaU5hRWVOdDJlNG5JM2JFX0ZoUkxjd3JrOVExSkZpNnMySUtpejZZMUgxWU94NDh6aHVCUHZPTHJNSnB4MFNGVk5zZmh0VURUdUhPbEJJcnlPcGRMSkZqZkd2ZXBxQ2NSY2p0LTdjN0s3M082akFnWTBVNG1uancyX0s5T1A0RFMxU19qNVRKaUI?oc=5","date":"2024-10-30","type":"pipeline","source":"ScienceNorway","summary":"Hormonal IUD and breast cancer: \"Wrong for women to be scared\" - ScienceNorway","headline":"Hormonal IUD and breast cancer: \"Wrong for women to be scared\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9JYXRCTmlVekVuRHVrTUZVRnhZbHJpSDFpSVF1eFhRLXZ3dmx1enB3R1NjUGhJRjlWVkF0NUpwRF8wRnZHMXBEVHBOWTVvSmtMUWE5Z2VueFB3U3RpZFMxcENjVDNiSFRTa0ZnVzFZdFlwOHc?oc=5","date":"2023-10-13","type":"pipeline","source":"California Department of Corrections and Rehabilitation - CDCR (.gov)","summary":"CDCR Week in Review: October 13, 2023 - California Department of Corrections and Rehabilitation - CDCR (.gov)","headline":"CDCR Week in Review: October 13, 2023 - California Department of Corrections and Rehabilitation - CDCR (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOTXU3T3haVEFJbml3OVVBRi1semx3N01rYkdHVXl1R19peDJMY3d6YWQ3eFZybG5WTjUtLXVBVzBOVXRyRE1xTXFwdV9SQjdCR2tJS2t5QkdrUlhGa1JRQ1VPejdmUFAycTh3YlAyQWlVUUNwSjRvaGt5ZHN4cklBSURpbnlzOWRQZVZnMzVHazRHUFBjcVdfa3dNUVZuZnBQUG1oUGZ5ZjFqLVhrbVhtZkFyeUFfaEd5eVJoTjdDVldTMVNZUUxET0JiR2pEZ0h1bUk3M1V6LTJVU3hDX1c0YWJzVFNWNDZtc3dPX1VtcGc2QVpHa05wOUdlaUgxb055V2s2V0Y2a1pONC01bEpMcThJYWJfakg3?oc=5","date":"2023-02-13","type":"pipeline","source":"prnewswire.com","summary":"Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) - prnewswire.com","headline":"Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSTnZzcVpvN1NmZFR6VXdKbVVHWS1uUmU3ZWlZaGVfdXVBaEh3ZDh1Sm80dWY4bG1LV25sa0c0UzZoMmdhNWZBSWtjdldlUUdXM084alNMNF9pbEZQZV9n?oc=5","date":"2022-12-08","type":"trial","source":"Nature","summary":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial - Nature","headline":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-b","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE00cU1ZRnVZR3hQMTVYS2g2N2h2djdFYUJmMkhoZ2pEVUlSVnF0VWdQX2pXNVN5ZnZ2Y1NsUEl1YnluS19aT2l2MTF6bU13djF6VWJtcU9kWQ?oc=5","date":"2021-04-01","type":"trial","source":"ASCO Publications","summary":"Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example - ASCO Publications","headline":"Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0wb0dhRU9oUk80Vk1jXzkyYnpya0htRTZoLTVhM0ZnWDdSRkJsNzkxOFpyeVVSSWtXUTlBYm5EWnNqUXMxaWxlbUVUTXlXakRmR2o5cGc4dVU3TW9yMElZ?oc=5","date":"2018-05-01","type":"trial","source":"NEJM","summary":"A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer - NEJM","headline":"A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Brea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFA4d3BVakFkMUExZG1qb1RnYmtCQUo4Z3BvVWozeFBKdk9XWnZKeWVBRTlrbW5zUTBLQWNjQndBYlVucVF6c2tuNFBRTU44SGxjQTA2Vkx3Z1lDeWNqR2JZdlc0UHppWmtjOFF2d1lwcXFTOXdYZDUxTQ?oc=5","date":"2017-11-10","type":"pipeline","source":"Pharmacy Times","summary":"Warfarin May Reduce Risk of Cancer - Pharmacy Times","headline":"Warfarin May Reduce Risk of Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQcTAyN2xuaktFUE9EeWdITTVFYU1UN2JoZTU3N2dwZlRGRWlGN3VtV2Jvbk1BUTRtUHV6Q0hjS1NaaHFabm9UQ0ZUeEdrVEZnb21VSjZSR3Vkd0pSWjZrbWxrdFRoZVdKUk1nRjhRWnAwenVISFlwOUNoNVBuWFFWRkpFeUxSYzdFS3pCQk4tV1k4QWV2?oc=5","date":"2017-10-27","type":"pipeline","source":"Tidsskrift for Den norske legeforening","summary":"Chronic fatigue in adult cancer survivors - Tidsskrift for Den norske legeforening","headline":"Chronic fatigue in adult cancer survivors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOeEtJeTlNdFEwN1ZkRzd4RVp5enhYX3BMbjU3UkR5MTEteHhQMnV5RGJJajFyN2Z3cEN1MmRCRlBmSVVYQk5wbTVaNDlUYVdHc0VVNjEyNzhpdndDT1NySS1sQWNnQ2lmelcxVDRYMlVUcEh1eXB2OUpJUHdlbDhld1lfQlZ3eFM4ejctWHhtMk81WEdWN2VTX2thT1RGRHB4XzhxNW55NEhSNGNIdDJkTS04T3RHMkFjQ3drVXVVaXVaR2duVVh2c0pwYw?oc=5","date":"2015-06-05","type":"trial","source":"Fierce Pharma","summary":"Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors - Fierce Pharma","headline":"Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Pa","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}